Drug Repurposing

Leading Drug Repurposing Efforts

The Center for Cytokine Storm Treatment & Laboratory (CSTL), under the leadership of Dr. David Fajgenbaum, is committed to the discovery of new uses for existing drugs to save patients’ lives. There are ~3,000 drugs currently FDA approved to treat ~4,000 of the ~18,000 human diseases. No treatments exist for the vast majority of diseases, many of which are rare and deadly. The CSTL is leveraging laboratory and computational approaches to rapidly identify and advance drug repurposing opportunities for Castleman disease and other immune-related conditions.

Check out these papers describing this work:

Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman’s Disease. New
England Journal of Medicine, 2025.

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric
Castleman disease. Blood Advances, 2021.

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory
idiopathic multicentric Castleman disease. Journal of Clinical Investigation, 2019.